People: Neurotrope Inc (NTRP.OQ)

NTRP.OQ on NASDAQ Stock Exchange Capital Market

20 Sep 2019
Change (% chg)

$-0.08 (-8.37%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Alkon, Daniel 

Dr. Daniel Alkon, M.D., serves as President, Chief Scientific Officer of the Company. Dr. Alkon has been the founding Scientific Director of BRNI since 1999. He received his undergraduate degree in chemistry in 1965 at the University of Pennsylvania. After earning his M.D. at Cornell University and finishing an internship in medicine at the Mount Sinai Hospital in New York, he joined the staff of the National Institutes of Health where during his 30 year career he became a Medical Director in the U.S. Public Health Service at the National Institute of Neurological Disorders and Strokes and Chief of the Laboratory of Adaptive Systems. Dr. Alkon occupied the Toyota Chair in Neurodegenerative diseases at BRNI from June 2006 until September 23, 2016. In this position, he and his team conducted multidisciplinary research on the molecular and biophysical mechanisms of memory and memory dysfunction in psychiatric and neurological disorders, particularly Alzheimer’s disease. From October 2000 until September 23, 2016, he was also a Professor at BRNI and a Professor of Neurology at West Virginia University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --